A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Clinical Trial to Evaluate the Safety, Pharmacokinetic and Pharmadynamics of JW0061 Following Topical Application in Korean and Caucasians Healthy Adults
Latest Information Update: 02 May 2026
At a glance
- Drugs JW 0061 (Primary)
- Indications Alopecia
- Focus Adverse reactions
- Sponsors JW Pharmaceutical
Most Recent Events
- 23 Apr 2026 Status changed from not yet recruiting to recruiting.
- 10 Apr 2026 New trial record